newsfilter
← Earnings
Earnings Releases·

HCW Biologics — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Revenues for the three months ended September 30, 2026, were $55,463, compared to $15,606 in the same period in 2025.
    • Revenues for the nine months ended September 30, 2026, were $6.7 million, compared to $27,222 in the same period in 2025.
    • Research and development (R&D) expenses for the three months ended September 30, 2026, were $1.2 million, a 12% decrease from $1.4 million in 2025.
    • R&D expenses for the nine months ended September 30, 2026, were $3.7 million, a 10% decrease from $4.1 million in 2025.
    • General and administrative (G&A) expenses for the three months ended September 30, 2026, were $1.4 million, a 28% decrease from $1.8 million in 2025.
    • G&A expenses for the nine months ended September 30, 2026, were $5.1 million, an 18% decrease from $6.2 million in 2025.
    • Net loss for the three months ended September 30, 2026, was $3.2 million, compared to $4.6 million in 2025.
    • Net loss for the nine months ended September 30, 2026, was $5.0 million, compared to $8.7 million in 2025.
    • Cash and cash equivalents were $955,458 as of September 30, 2026, down from $1,952,464 as of December 31, 2025.
    • Deferred revenue was $297,101 as of September 30, 2026, compared to zero in the prior period.
    • Short-term debt, net, was $6.8 million as of September 30, 2026, compared to $6.8 million as of December 31, 2025.
    • Total liabilities were $18.3 million as of September 30, 2026, down from $21.8 million as of December 31, 2025.
  • Guidance and Future Outlook:

    • The Company expects the Phase 1 readout and determination of the Recommended Phase 2 Dose for HCW9302 in the first quarter of 2027.
    • The Company intends to file an IND application for HCW11-018b in solid tumors in the first half of 2027.
    • The Company anticipates presenting full Phase 1 clinical trial results for HCW9302 at the 9th Treg-Directed Therapies Summit in March 2027.
    • As of September 30, 2026, the Company believes substantial doubt exists regarding its ability to continue as a going concern for at least 12 months without additional funding or financial support.
    • The Company believes it has funding in place to reach the milestone of completing the Phase 1 clinical trial for HCW9302 and determining the Recommended Phase 2 Dose level.
  • Business Segments and Product Lines:

    • The Company activated an additional clinical site for the HCW9302 Phase 1 clinical study in alopecia areata, with patient enrollment continuing in the third dose cohort (8 micrograms/kg).
    • HCW9302 has been well-tolerated with no dose-limiting toxicities in patients treated to date.
    • The Company showcased two preclinical, non-Fc TRBC molecules at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC2026).
    • The Company's second-generation, tetravalent immune checkpoint inhibitor, HCW11-040, was recognized by SITC2026 as one of the top 150 abstracts out of over 1,200 submitted.
    • The Company shared data on its lead T Cell Engager, HCW11-018b, highlighting capabilities to induce tertiary lymphoid structure formation, convert "cold" tumors to "hot" tumors, and enhance T-cell activation.
    • The Company initiated cGMP manufacturing of HCW11-018b and created a high-expression production cell line with a streamlined GMP manufacturing process.
    • The Company completed the closing of an exclusive, worldwide licensing agreement with Beijing Trimmune Biotech Co., Ltd. for the in vivo rights for HCW11-006.
    • The Company terminated its license with AlloTera Therapeutics, Inc., recapturing exclusive rights to the licensed molecules.
  • Market and Competitive Landscape:

    • The Company is a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia.
    • The Company's immunotherapeutics utilize a unique protein-based scaffold without the antibody Fc domain.
    • The Company has entered into two licensing agreements for exclusive, worldwide rights to proprietary molecules.
  • Risks and Challenges:

    • Substantial doubt exists regarding the Company's ability to continue as a going concern for at least 12 months without additional funding.
    • The Company cannot be assured of success with remaining elements of its financing plan.
    • Forward-looking statements are subject to risks including timing and efficacy of clinical trial data, FDA clearance for Phase 2 trials, and the ability to license or sell reagents.
    • The Company anticipates continuing to incur expenses for compliance with the Settlement and Release Agreement from the Arbitration.
  • Management Commentary and Tone:

    • Dr. Hing C. Wong, Founder and CEO, stated progress continues steadily for the HCW9302 clinical study, with human results consistent with preclinical studies.
    • Management expressed hope that patient enrollment will maintain good momentum with the addition of a third clinical site.
    • Management expressed excitement about the progress made with the TRBC platform molecules, specifically HCW11-018b and HCW11-040, noting their potential to revolutionize treatment for solid tumors and senescence-associated diseases.
    • Management noted the support of strong clinical sites sharing their passion for developing breakthrough immunotherapeutics.
  • Other Key Points:

    • The Company raised $8.6 million of equity financing in the nine months ended September 30, 2026.
    • On November 4, 2026, the Company secured up to $10.0 million in debt financing, receiving $3.0 million at closing and access to an additional $7.0 million subject to conditions.
    • The Company received formal notice from Nasdaq on October 2, 2026, that it maintained compliance with the Bid Price Rule until September 22, 2026.
    • The Company received formal notice from Nasdaq on June 26, 2025, that it was in compliance with the Equity Rule.
    • Legal expenses (recoveries), net, were $14,483 for the nine months ended September 30, 2026, compared to a net recovery of $1.6 million in the same period in 2025.
    • A $1.8 million nonoperating loss was recorded in the nine months ended September 30, 2026, primarily consisting of a decrease in the fair value of a warrant liability reclassified to equity.
    • The Company received a $2.0 million insurance recovery in the nine months ended September 30, 2025, partially offset by $409,055 of legal expenses.
Company
HCW BIOLOGICS INC
Sector
Healthcare
Industry
Biotechnology